VEDO 2003: A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects WithUlcerative Colitis or Crohn's Disease.

Project: Research project

Project Details

StatusActive
Effective start/end date4/1/18 → 8/31/50

Funding

  • Takeda Pharmaceuticals